Follow-up Outcomes of Benign Pathology Initially Assigned as Breast Imaging Reporting and Data System Category 4A and 3

Ji Young You, Hee Jung Suh¹, Yunju Kim, Jae Kwan Jun², Haydee Ojeda-Fournier³, Kyounglan Ko

Center for Breast Cancer, Research Institute and Hospital;¹Cancer Prevention and Early Detection Center, and ²National Cancer Control Institute, National Cancer Center, Goyang, Korea;³Department of Radiology, Moores Cancer Center, UC San Diego Health System, La Jolla, USA

INTRODUCTION

The management plans are different depending on the pathology results. Immediate action should be taken in the case of concordant malignancy. If discordant benign lesions are obtained, surgical excision should be considered. For the concordant benign lesions, imaging follow-ups are recommended. Although the management plans for initial Breast Imaging Reporting and Data System (BI-RADS) category 4A and 3 are different, biopsy is the first option for initial category 4A, and regular imaging follow-up is preferable for initial category 3; in addition, if the expected cancer detection rates are different, discordant benign lesions obtained from initial category 4A and 3 are treated in the same manner [1].

Regarding discordant benign lesions, when benign core biopsy was obtained in an expected benign lesion on imaging study [2], follow-up is mandatory to confirm stability and to avoid possible delayed false-negative results. Many studies have proposed follow-up strategy for the discordant benign lesion [3-5]. Youk et al. [3] suggested beginning US follow-up at a minimum of 12 months if concordant benign lesions were observed after core needle biopsy, and if there were any symptoms, follow-up US should begin earlier, at least 6 months after core needle biopsy. Lee et al. [4] suggested that follow-up recommendation should be based on the type of benign histologic finding; a 6-month follow-up was recommended for nonspecific results, and an annual follow-up recommended for specific results. A preliminary report by Marcon et al. [5] showed that a 6-month follow-up might be sufficient to assess the stability of category 3 lesions in young patients.

Purpose: This retrospective study investigated if the initially assigned category 4A or 3 in concordant benign lesions, after ultrasound (US)-guided core needle biopsy, could affect follow-up compliance. Methods: Eight hundred thirty-eight concordant benign lesions, after core needle biopsy (674, initial category 4A group and 164, category 3 group) and follow-up US, were included in our study. If an immediate surgical excision—a surgical excision before the next follow-up—exists, those cases with pathologic reports were collected. Statistical comparisons for the result of follow-up US compliance, additional biopsy, and malignant rates among 6-month, 12-month, and long-term intervals were performed by using the chi-square test. The log-rank test was used to compare compliance rates in the timing of first follow-up between the two groups, with a significance level of 0.05. Results: The number of immediate surgical excision was higher in the category 4A group (11.1%) than in the category 3 group (6.1%); only one cancer was found in the category 4A group. The patients’ compliance rate in a 6-month follow-up showed an increase ($p=0.003$) in the category 4A group. The additional biopsy rate was higher in the initial category 4A group (10.9%) than in the category 3 group (1.9%) with statistical significance ($p=0.001$); four cancers were found on additional biopsy in the category 4 group. No cancer was detected in the initial category 3 group, both on immediate surgical excision and follow-up. Conclusion: The initial category 4A or 3 of the Breast Imaging Reporting and Data System could be a significant factor that affects immediate surgical excision and follow-up compliance. Cancers were detected only in the initial category 4A group of concordant benign lesions. More attention should be paid to the discordant benign lesions from the initial category 4A group than from the category 3 group.

Key Words: Breast neoplasms, Diagnostic imaging, Follow-up studies, Image-guided biopsy
According to the American College of Radiology’s BI-RADS (ACR BI-RADS), the likelihood of cancer in category 4A is known to be 2% to 10% and that of category 3 is 0% to 2% [1]. Although there is a significant difference in the likelihood of cancer between the two groups, previous publications concentrated on mainly pathology results obtained from the biopsy [3-5] and any articles dealing with the effect of the initial BI-RADS category have not been released. The purpose of this study was to investigate if the initial category 4A or 3 in concordant benign lesions could affect follow-up compliance.

**METHODS**

This retrospective, single-institution, observational study was approved by the Institutional Review Board of the National Cancer Center of South Korea (IRB number: 2014-0064), and the requirement for informed consent was waived.

**Study design**

We identified 1,955 cases of consecutive ultrasound-guided, 14-gauge core needle biopsies conducted in 1,787 women (mean age, 44 ± 9.7 years) from June 2009 to December 2011. From these, data for 1,254 lesions (1,084, initial category 4A and 170, initial category 3) were obtained (Figure 1). Among the 1,084 cases of the initial category 4A group, we excluded 410 cases where surgical removal of ipsilateral breast cancers had been performed simultaneously in the initial category 4A (25 cases), when discordant results such as malignancy or high-risk lesions were obtained (228 cases), and when the initial category 4A lesions were surgically removed with other breast lesions without any pathologic reporting (157 cases). Among the 170 initial category 3 cases, six cases were excluded because of discordant pathology (four cases) and simultaneous surgical removal without any pathologic report about it (two cases). The rest of the 838 lesions (674, category 4A and 164, category 3) of concordant benign results were included in this study (Figure 1). Concordant benign lesions of initial category 4A group were 674 lesions in 674 patients (mean age, 45.3 ± 9.6 years) and that of category 3 group were 164 lesions in 164 patients (mean age, 43.4 ± 10.1 years).

**Biopsy technique**

We evaluated breast lesions and assessed the possibility of malignancy based on the BI-RADS-Ultrasound lexicon [1]. Among them, BI-RADS category 4 or higher lesions were indications for core needle biopsy. On the request of patients or referring physicians, BI-RADS category 3 lesions were referred to undergo core needle biopsy. The freehand technique was used during US-guided gun biopsy, using a 7.5–12 MHz linear array transducer (Philips Advanced Technology Laboratories, Bothell, USA). An automated (TSK Laboratory, Tochigi, Japan) or semi-automated gun (TSK Laboratory) was selected as per the radiologists’ preferences. One to four breast radiologists performed US-guided biopsy when the specimen contained four to six core samples per lesion.

**Data collection**

After biopsy, the decision about concordance or discordance was determined via a consensus conference. A concordance decision meant the pathologic findings provided an appropriate explanation for the imaging abnormality and discordance meant they did not [2]. If malignant pathology was

---

**Figure 1.** Flow chart of study population. US = ultrasound.
obtained in category 4B, 4C, and 5, it was considered as concordant malignancy and if benign pathology was obtained in the same categories, it was considered as discordant benign. If malignant pathology was obtained in category 4A and 3, it was considered as discordant malignancy and if benign pathology was obtained in the same categories, it was considered as concordant benign.

If malignancy was found in core needle biopsy, immediate action such as surgery or chemotherapy, were taken. In cases of high-risk lesions (atypical hyperplasia, lobular carcinoma in situ, papillary lesions, phyllodes tumor, mucocle-like lesion, and radial scars), we recommended excisional biopsy through surgical excision or vacuum-assisted devices. For concordant benign lesions, follow-up US after 6 months after biopsy and annually thereafter for minimum 2 years was recommended in either initial category 4A or 3 lesions.

Analysis of follow-up data

If a surgical excision was performed before the next follow-up, we defined it as an immediate surgical excision. We gathered those cases and evaluated the pathologic reports. If the immediate surgical excision was performed, the follow-up was considered to be terminated. Dates of each imaging study, performed subsequent to the initial biopsy, were recorded and grouped into intervals: 6-month follow-up (≤9 months), 12-month follow-up (>9, ≤15 months), and long-term follow-up (>15, ≤36 months). Regarding US follow-up after core needle biopsy, details of the number and the result of follow-up US were comprehensively recorded in both category 4A and 3.

Any changes during follow-up such a development of suspicious findings or progression of previous lesion, the results of additional biopsy performed were recorded. We defined the additional biopsy as performing biopsy in either another newly developed lesion or the same lesion with size enlargement or lesion character changes during the first follow-up.

We evaluated whether the initial category might affect the patients’ compliance during the follow-up, in concordant benign lesions with initial category 4A or 3 groups. We also investigated whether additional biopsy rate and the cancer detection rate was related to the initial category, when the patient came for follow-up.

Statistical analysis

Statistical comparisons for the result of first follow-up US compliance and malignant rates among 6-month, 12-month, and long-term intervals were performed by using the chi-square test. A p-value less than or equal to 0.05 was considered to be statistically significant. Kaplan-Meier curves were plotted, and the log-rank test was used to compare the compliance rate in the timing of first follow-up between the two groups, with a significance level of 0.05. All statistical analyses were performed with STATA version 10.0 (StataCorp LP, College Station, USA) software.

RESULTS

Immediate surgical excision was performed for the radiologic-pathologic concordant benign lesion based on some clinical symptoms such as a palpable lump or nipple discharge, or at the requests of clinicians or patients. The rate of immediate surgical excision was higher in the category 4A group than in the category 3 group, 75 cases (11.1%, 75/674) versus 10 cases (6.1%, 10/164). Only one cancer was confirmed in the category 4A group, a ductal carcinoma in situ arising in a fibroadenoma, in a patient who had a palpable lump (Table 1), with the initial biopsy diagnosis being florid ductal hyperplasia. The prevalence of malignancy in the excisional biopsy was 1.3% in the category 4A group and 0% in the category 3 group. Seventeen high-risk lesions (four atypical ductal hyperplasias, 10 intraductal papillomas, and three benign phyllodes tumors) were confirmed in the category 4A group (22.7%, 17/75) through immediate surgical excision. Initial core needle biopsy results of 17 high-risk lesions were as follows: three fibroadenomas, proved to be benign phyllodes tumors; one juvenile fibroadenoma; one usual ductal hyperplasia; two cases of sclerosing adenosis turned out to be atypical ductal hyperplasia; three cases of sclerosing adenosis; three cases of fibrocystic change; two cases of fibroadenoma; one microglandular adenosis; and one florid ductal hyperpla-

Table 1. Reason for immediate surgical excision and pathology

| Reasons and pathology | Category 4A | Category 3 |
|-----------------------|-------------|------------|
| Reason of excision    |             |            |
| Palpable              | 49          | 6          |
| Nipple discharge      | 4           | 0          |
| Request by patients or clinician | 22 | 4 |
| Pathology             |             |            |
| DCIS                  | 1           | 0          |
| ADH                   | 4           | 0          |
| IDP                   | 10          | 0          |
| Phyllodes             | 3           | 0          |
| Fibroadenoma          | 39          | 6          |
| Fibrocystic change    | 16          | 3          |
| Hamartoma             | 1           | 0          |
| Tubular adenoma       | 1           | 0          |
| Sclerosing adenosis   | 0           | 1          |
| Total                 | 75          | 10         |

DCIS=ductal carcinoma in situ; ADH=atypical ductal hyperplasia; IDP=intraductal papilloma.
Table 2. Comparison of follow-up compliance and the first follow-up intervals according to the initial radiological category

| Timing of 1st follow-up | Compliance rate | Addition biopsy | Cancer detected on additional biopsy |
|-------------------------|-----------------|-----------------|-------------------------------------|
|                         | Category 4A No. (%) | Category 3 No. (%) | p-value | Category 4A No. (%) | Category 3 No. (%) | p-value | Category 4A No. (%) | Category 3 No. (%) | p-value |
| 6 Months*               | 293 (48.9)       | 54 (35.1)       | 0.003   | 44 (15.0)       | 2 (3.7)        | 0.042   | 3 (6.8)         | 0         | NA      |
| 12 Months†              | 116 (19.4)       | 32 (20.8)       | 0.779   | 14 (12.1)       | 0              | 0.085   | 0              | 0         | NA      |
| Long-term‡              | 32 (5.3)         | 13 (8.4)        | 0.209   | 7 (21.9)        | 1 (7.7)        | 0.485   | 1 (14.3)       | 0         | NA      |
| Follow-up loss          | 158 (26.4)       | 55 (35.7)       | 0.028   | -              | -              | -       | -              | -         | -       |
| Total                   | 599 (100)        | 154 (100)       | NA      | 65 (10.9)       | 3 (1.9)        | 0.001   | 4 (6.2)        | 0         | NA      |

Dates of each imaging study performed subsequent to the initial biopsy were grouped into intervals. NA = not applicable. *≤ 9 months follow-up; †> 9, ≤ 15 months follow-up; ‡> 15, ≤ 36 months follow-up.

Figure 2. Compliance rate in the timing of first follow-up. The patients with initial category 4A showed higher compliance rate than that of category 3 with statistical significance (log-rank p = 0.015).

BI-RADS = Breast Imaging Reporting and Data System.

Table 2 shows that the compliance rate is higher in the initial category 4A group (73.6%) compared with the category 3 group (64.2%) in the first 12 months follow-up. The follow-up rate in the concordant benign group, the initial BI-RADS category before core needle biopsy might affect the follow-up compliance especially on the 6-month follow-up.

Except for the cases lost to follow-up, the remaining 441 category 4A cases and 99 category 3 cases were analyzed (Table 2). The additional biopsy rate was higher in the initial category 4A group (10.9%) compared with the category 3 group (1.9%) with statistical significance (p = 0.001). Most of the additional biopsy was performed within 6 months in the initial category 4A group. We found four cases of malignancy and all of them were from initial category 4A and were carcinomas in situ (one, intraductal papillary carcinoma and three, ductal carcinomas in situ). Regardless of the follow-up timing, the malignancy detection was observed in the category 4A group only.

**DISCUSSION**

About one million minimally invasive breast biopsies are performed in the United States each year, with about 75% yielding benign results [6]. Delayed diagnosis of missed cancers has been reported in concordant benign results obtained after image-guided biopsy [7,8]. Decisions for interval imaging in patients with core needle biopsies should be individualized based on imaging and pathologic findings. Although ACR BI-RADS’s recommendation for category 3 lesions was an observation with regular period imaging, biopsies in category 3 lesions were performed in practices for several reasons, as follows: when the patients were transferred from private clinics, or when there was a discrepancy in interpretations between a clinician and a radiologist, or when the patient had clinical symptoms such as a palpable lump, pain, or nipple discharge associated with definite benign images, or when the breast lesions were found accidentally on other imaging modalities. There are several publications related to follow-up of concordant benign lesions [3,4] or follow-up of category 3 le-
sions [9-11], but there were no reports about category 4A concordant benign follow-up or category 3 concordant benign follow-up. In this context, we hypothesized that because the initial category 4A or 3 was an important determinant for making a decision about percutaneous biopsy, it could affect even concordant benign results obtained after percutaneous biopsy from either category 4A or 3.

ACR BI-RADS recommends the likelihood of cancer in category 4A to be from 2% to 10% and that of category 3 to be less than 2% [1]. We performed immediate surgical excisions if patients had clinical symptoms or if clinicians preferred excision to follow-up. The rate of immediate surgical excision in concordant benign cases was higher in the category 4A group than in the category 3 group and malignancy was confirmed only in patients with palpable lump in the category 4A group, which was confirmed as a ductal carcinoma in situ arising with a fibroadenoma. Liberman et al. [8] reported missed cancer like ours and our results could give power to the reliability of the BI-RADS recommendations by verifying that immediate surgical excision should be suggested if the patient in a higher category group had any clinical symptoms. Twenty-two initial category 4A lesions and four initial category 3 lesions were surgically excised before the next imaging follow-up, on the request of patients or clinicians, and no malignancy was found. If patients with concordant benign lesions did not have clinical symptoms, such as a palpable lump or nipple discharge, regular periodical imaging follow-up would be sufficient.

In our study, the compliance rate of initial category 4A was 73.6% and that of category 3 was 64.3%. We found a statistically higher follow-up rate of category 4A than category 3 on the 6-month follow-up, although this trend did not show any change in longer follow-ups, which means that the initial category before core needle biopsy affected the follow-up intervals. The clinicians might explain to the patients actively about the malignant risk of their breast lesions on following the ACR BI-RADS category or explain to the patients who already know the benign biopsy results so they did not find re biopsy a necessity. The reported compliance rate of BI-RADS 3 ranged from 63% to 71% [12].

Manjoros et al. [13] reported that interval imaging performed within 12 months after detection of benign concordant breast biopsy demonstrated a low yield for the detection of breast cancer. Salkowski et al. [7] suggested that yearly follow-up might be more appropriate because 6-month follow-up imaging for benign concordant lesions did not aid in detection of breast cancers or influence recommended rebiopsy rates. Youk et al. [14] also recommended that in case of presence of discordant benign lesions after US-guided core needle biopsy, US follow-up should begin at minimum 12 months after core needle biopsy, considering that earlier the diagnosis, the better the prognosis. However, follow-up US should begin earlier, at 6 months after core needle biopsy, for discordant benign lesions associated with any clinical symptoms [3]. Similar to that described in these reports, lesions with clinical symptoms were surgically excised in our study group before the next imaging follow-up and only one cancer was found in initial category 4A group.

Our result showed a higher additional biopsy rate in the initial category 4A group than in the initial category 3 group, with statistical significance. In addition, the cancer detection frequency on additional biopsy showed slightly higher trend in the initial category 4A group than in the category 3 group, especially on 6-month follow-ups. More attention should be paid to the initial category 4A group than the category 3 group during the 6-month follow-ups, as the chances for performing additional biopsy and finding a potential cancer are high at this time point.

Our study had several limitations. First, as a retrospective study, there was a lack of randomization. There was variability in actual follow-up times, likely influenced by multiple factors, including patient or referring physician preference, or insurance criteria. This could be a potential source of bias. Second, despite the large number of US-guided biopsies performed with available follow-up information, the actual number of patients that were included in our study was small. This might have excluded missed cancers that had been present in the population but were lost to follow-up, resulting in a lower than expected cancer yield with imaging interval. Third, the decision for additional biopsy was based on the change in imaging findings in the follow-up group and the clinical symptoms were not taken into consideration. Last, the pathologic slides of core or surgical specimens were not re-reviewed retrospectively by a pathologist and the original pathologic report was accepted.

Despite several limitations, initial category 4A or 3 of ACR BI-RADS could be a significant factor that affects follow-up compliance and even immediate surgical excision. It is related to a significantly high additional biopsy rate and clinically high cancer detection in the initial category 4A group. More attention should be paid to the discordant benign lesions from the initial category 4A group than from the category 3 group.

**CONFLICT OF INTEREST**

The authors declare that they have no competing interests.
Does Initial BI-RADS Category Affect the Follow-up Outcome?

ACKNOWLEDGMENTS

I would like to thank Dr. Seri Hong, who helped me statistical support.

REFERENCES

1. American College of Radiology. Breast Imaging Reporting And Data System (BI-RADS®). 4th ed. Reston: American College of Radiology; 2003.
2. Parikh J, Tickman R. Image-guided tissue sampling: where radiology meets pathology. Breast J 2005;11:403-9.
3. Youk JH, Jung I, Kim EK, Kim MJ, Son EJ, Moon HJ, et al. US follow-up protocol in concordant benign result after US-guided 14-gauge core needle breast biopsy. Breast Cancer Res Treat 2012;132:1089-97.
4. Lee CH, Philpotts LE, Horvath LJ, Tocino I. Follow-up of breast lesions diagnosed as benign with stereotactic core-needle biopsy: frequency of mammographic change and false-negative rate. Radiology 1999;212:189-94.
5. Marcon M, Frauenfelder T, Becker AS, Dedes KJ, Boss A. First ultrasound diagnosis of BI-RADS 3 lesions in young patients: can 6-months follow-up be sufficient to assess stability? Eur J Radiol 2017;89:226-33.
6. Sickles EA. Probably benign breast lesions: when should follow-up be recommended and what is the optimal follow-up protocol? Radiology 1999;213:11-4.
7. Salkowski LR, Fowler AM, Burnside ES, Sisney GA. Utility of 6-month follow-up imaging after a concordant benign breast biopsy result. Radiology 2011;258:380-7.
8. Liberman L, Drotman M, Morris EA, LaTrenta LR, Abramson AF, Zakowski MF; et al. Imaging-histologic discordance at percutaneous breast biopsy. Cancer 2000;89:2538-46.
9. Chae EY, Cha JH, Shin HJ, Choi WJ, Kim HH. Reassessment and follow-up results of BI-RADS category 3 lesions detected on screening breast ultrasound. AJR Am J Roentgenol 2016;206:666-72.
10. Graf O, Helbich TH, Hopf G, Graf C, Sickles EA. Probably benign breast masses at US: is follow-up an acceptable alternative to biopsy? Radiology 2007;244:87-93.
11. Raza S, Chikarmane SA, Neilsen SS, Zorn LM, Birdwell RL. BI-RADS 3, 4, and 5 lesions: value of US in management--follow-up and outcome. Radiology 2008;248:773-81.
12. Borders MH, Cheng L, Fitzpatrick KA, Krupinski EA. Patient compliance in the setting of BI-RADS category 3: what factors impact compliance with short-term follow-up recommendations? Breast J 2017;23:77-82.
13. Manjoros DT, Collett AE, Alberty-Oller JJ, Frazier TG, Barrio AV. The value of 6-month interval imaging after benign radiologic-pathologic concordant minimally invasive breast biopsy. Ann Surg Oncol 2013;20:3163-8.
14. Youk JH, Kim EK, Kim MJ, Kwak JY, Son EJ. Analysis of false-negative results after US-guided 14-gauge core needle breast biopsy. Eur Radiol 2010;20:782-9.